Then, Wei should claim much much more than this to suppot his paper.



所有跟贴·加跟贴·新语丝读书论坛http://www.xys.org/cgi-bin/mainpage.pl

送交者: lijun 于 2006-4-19, 08:44:55:

回答: ZT: 有一篇Nature Medicine的独立文章完全支持魏于全的观点 由 Cheval 于 2006-4-19, 07:02:16:

1. Identification of the relationship between VEGFR-2 and angiogenesis.
2. Discovery of VEGFR-2 as a target for cancer therapy;
3. Monoclonal antibodies and small molecules targeting VEGFR-2 as anti-cancer drugs;
4. Discovery and development of drugs like Nexavar (sorafenib) by Bayer approved by FDA in 12/2005, and Sutent (sunitinib maleate) by Pfizer aprroved by FDA in 1/2006.
5. All drug candidates at clinical trials such as AMG706
by Amgen, Zactima (ZD6474) by AstraZeneca, PKC412 and AEE 788 by Norvatis, AG-013736 by Pfizer, and many others.

After all, Wei is the father of VEGFR-2 and any related scientific discovery and commercial products.






所有跟贴:


加跟贴

笔名: 密码(可选项): 注册笔名请按这里

标题:

内容(可选项):

URL(可选项):
URL标题(可选项):
图像(可选项):


所有跟贴·加跟贴·新语丝读书论坛http://www.xys.org/cgi-bin/mainpage.pl